Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3
作者：
Zhou, C. [1 ]
Cheng, Y. [2 ]
He, Y. [3 ]
Li, W. [4 ]
Zhang, H. [5 ]
Zhou, Q. [6 ,7 ]
Wang, B. [8 ]
Liu, C. [9 ]
Ramalingam, S. [10 ]
Walding, A. [11 ]
Saggese, M. [11 ]
Wang, J. [12 ]
Fan, M. [12 ]
Wu, Y. [6 ,7 ]
机构：
[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China
[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China
[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China
[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China
[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China
[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[11] Astrazeneca, Global Med Dev, Cambridge, England
[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
osimertinib; China; NSCLC;
D O I：
10.1016/j.jtho.2018.08.669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-112
引用
收藏
页码：S507 / S508
页数：2
相关论文
共 50 条
[21]   T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI [J].
Ren, Shengxiang ;
Li, Wei ;
Li, Aiwu ;
Chen, Xiaoxia ;
Gao, Guanghui ;
He, Yayi ;
Li, Xuefei ;
Zhou, Caicun .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S1084-S1084
[22]   EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC [J].
Moore, Sara ;
Wheatley-Price, Paul .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) :1788-1792
[23]   The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib [J].
Chen, Kuan-Chih ;
Huang, Yen-Hsiang ;
Hsu, Kuo-Hsuan ;
Tseng, Jeng-Sen ;
Chang, Gee-Chen ;
Yang, Tsung-Ying .
ONCOTARGETS AND THERAPY, 2023, 16 :317-326
[24]   Oral Vinorelbine Monotherapy in Patients with EGFR plus NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study [J].
Kowalski, Dariusz ;
Banna, Giuseppe Luigi ;
Ramlau, Rodryg ;
Ceresoli, Giovanni ;
Camerini, Andrea ;
Milanowski, Janusz ;
Caruso, Michele ;
Landreau, Philippe ;
Vedovato, Jean-Claude ;
Tang, Eng Huat .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1217-S1218
[25]   Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC [J].
Jiang, Wei ;
Zeng, Aiping ;
Ning, Ruiling ;
Zhao, Wenhua ;
Su, Cuiyun ;
Wang, Huilin ;
Zhou, Shaozhang ;
Yu, Qitao .
ONCOLOGY LETTERS, 2020, 19 (06) :3859-3870
[26]   ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib [J].
Cho, B. C. ;
Piotrowska, Z. ;
Le, X. ;
Goldberg, S. B. ;
Goldman, J. ;
De langen, A. ;
Okamoto, I. ;
Smith, P. ;
Mensi, I. ;
Maidment, J. ;
Hartmaier, R. ;
Li, M. ;
Doughton, G. ;
Patel, G. ;
Pease, J. ;
Szekeres, P. ;
Riess, J. ;
Yu, H. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S598-S598
[27]   Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation [J].
Osoegawa, Atsushi ;
Karashima, Takashi ;
Takumi, Yohei ;
Sato, Takahiro ;
Abe, Miyuki ;
Hashimoto, Takafumi ;
Sugio, Kenji .
JOURNAL OF THORACIC DISEASE, 2023, 15 (10) :5566-5573
[28]   Treatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR-TKI therapy [J].
Shen, Cailu ;
Zhang, Siying ;
Wang, Xiaoli ;
Shen, Di ;
Ge, Xiaosong ;
Mao, Yong .
MOLECULAR AND CLINICAL ONCOLOGY, 2025, 23 (03)
[29]   Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance [J].
Zhang, Yidan ;
Xu, Yingqi ;
Xu, Jianlin ;
Zhong, Hua ;
Xia, Jinjing ;
Zhong, Runbo .
CANCER SCIENCE, 2024, :753-763
[30]   EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC [J].
Stock-Martineau, Sophie ;
Shepherd, Frances A. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) :1793-1797
12345